At the moment, only a certain segment of lung cancer patients benefit from immunotherapy. For instance, people with a protein called PD-L1 on their cancer cells respond well to immunotherapy drugs, like Keytruda, that block the protein, thus unleashing the immune system to recognize and attack cancer cells. PD-L1 is just one of dozens of different molecules that play a role in how cancer interacts with and evades the immune system.
Clinical trials are looking at antibodies or blockers for some of the other molecules that will likely expand the number of people with lung cancer who will benefit from immunotherapy.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Ronald Natale is Director of the Lung Cancer Clinical Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center in Los Angeles. Read More
At the moment, only a certain segment of lung cancer patients benefit from immunotherapy. For instance, people with a protein called PD-L1 on their cancer cells respond well to immunotherapy drugs, like Keytruda, that block the protein, thus unleashing the immune system to recognize and attack cancer cells. PD-L1 is just one of dozens of different molecules that play a role in how cancer interacts with and evades the immune system.
Clinical trials are looking at antibodies or blockers for some of the other molecules that will likely expand the number of people with lung cancer who will benefit from immunotherapy.
Read More
